Medtronic PMA for Extravascular ICD Approved
FDA has approved a Medtronic PMA for the Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan defibrillation lead for treating fast heart rhythms that can lead to sudden cardiac arrest. “The Aurora EV-ICD system is the first-of-its-kind to provide the life-saving benefits of traditional, transvenous ICDs with a lead (thin wire) placed under the breastbone, outside of the heart and veins,” the company says. “The Aurora EV-ICD delivers lifesaving defibrillation, anti-tachycardia pacing (ATP), and back-up (pause-prevention) pacing therapies via a device similar in size, shape, and longevity to traditional, transvenous ICDs.”
The approval was based on data showing that the device’s effectiveness in delivering defibrillation therapy at implant was 98.7%, and “there were no major intraprocedural complications, nor any unique complications observed related to the EV ICD procedure or system compared to transvenous and subcutaneous ICDs,” Medtronic says. “Additionally, 33 defibrillation shocks were avoided by having ATP – which paces the heart to interrupt and terminate a dangerous rhythm – programmed ‘on.’” The company also notes that at six months, 92.6% of patients were free from major system or procedure-related major complications (hospitalization, system revision, or death).